Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| 8LaBV | 8LaBV26 | U.S. | 1994 | HIV1 | B | Plasma | MMC |
Treatment History
| Order | Regimen | Weeks |
| 1 | NRTI+IDV | 26 |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| G48V, I54V, V82A | L10V, I62V, L63P, I64V, E65D |
| >8LaBV26| 22 | codons 1-99 | clone 22 PQITLWQRPVVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIVGIGGFVKVRQYD QVPVDICGHKAIGTVLVGPTPANIIGRNLLTQIGCTLNF >8LaBV26| 24 | codons 1-99 | clone 24 PQITLWQRPVVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIVGIGGFVKVRQYD QVPVDICGHKAIGTVLVGPTPANIIGRNLLTQIGCTLNF >8LaBV26| 25 | codons 1-99 | clone 25 PQITLWQRPVVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIVGIGGFVKVRQYD QVPVDICGHKAIGTVLVGPTPANIIGRNLLTQIGCTLNF >8LaBV26| 26 | codons 1-99 | clone 26 PQITLWQRPVVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIVGIGGFVKVRQYD QVPVDICGHKAIGTVLVGPTPANIIGRNLLTQIGCTLNF >8LaBV26| 28 | codons 1-99 | clone 28 PQITLWQRPIVTVKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFVKVRQYD QVPVDICGHKAIGTVLIGPTPFNIIGRNLLTQIGCTLNF >8LaBV26| 29 | codons 1-99 | clone 29 PQITLWQRPVVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIVGIGGFVKVRQYD QVPVDICGHKAIGTVLVGPTPANIIGRNLLTQIGCTLNF >8LaBV26| 30 | codons 1-99 | clone 30 PQITLWQRPVVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIVGIGGFVKVRQYD QVPVDICGHKAIGTVLVGPTPANIIGRNLLTQIGCTLNF >8LaBV26| 33 | codons 1-99 | clone 33 PQITLWQRPVVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIVGIGGFVKVRQHD QVPVDICGHKAIGTVLVGPTPANIIGRNLLTQIGCTLNF >8LaBV26| codons 1-99 PQITLWQRPVVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIVGIGGFVKVRQYD QVPVDICGHKAIGTVLVGPTPANIIGRNLLTQIGCTLNF |
References
| Author | Title | Citation |
| Zhang, Y-M | Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites. | J Virol, 1997 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |